ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma - Takeaways - MDSpire

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • By

  • June 14, 2026

  • 4 min

Share

  • 1

    The phase 2 ImmunoPRISM trial evaluated teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • 2

    Teclistamab achieved a complete response in 75.6% of patients, while none in the lenalidomide plus dexamethasone group achieved this.

  • 3

    Among evaluable patients, 82% in the teclistamab group became minimal residual disease-negative, compared to none in the combination therapy group.

  • 4

    Teclistamab significantly improved progression-free survival, with only 7% of patients progressing after 23.4 months, versus 36% in the combination group.

  • 5

    Cytokine release syndrome occurred in 71% of teclistamab patients, but all cases were low grade, with no neurological toxicities reported.

Original Source(s)

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

  • by

  • June 14, 2026

Related Content

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

An ASCO preview: What to watch for at cancer research’s big meeting

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

  • by

  • May 29, 2026

  • 5 min